Vabysmo

Roche reports data from Phase III retinal vein occlusion therapy trials
Clinical Trials Arena
Thu, 02/1/24 - 11:15 am
Roche
Vabysmo
macular edema
central retinal vein occlusion
Regeneron touts launch of high-dose Eylea in battle with Roche's Vabysmo
Fierce Pharma
Thu, 11/2/23 - 11:48 am
Regeneron
Eylea
Roche
Vabysmo
FDA Approves Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)
BioSpace
Fri, 10/27/23 - 11:34 am
Vabysmo
Genentech
Roche
retinal vein occlusion
Roche's Q3 sales down 3% on currency headwinds, drop in COVID sales
Reuters
Thu, 10/19/23 - 10:03 am
Roche
earnings
Vabysmo
Amid Eylea showdown, Roche's Vabysmo shows durability in retinal vein occlusion
Fierce Pharma
Wed, 10/11/23 - 10:13 am
Roche
retinal vein occlusion
Vabysmo
Roche’s Vabysmo reports positive outcomes in multiple eye diseases
Clinical Trials Arena
Thu, 07/20/23 - 10:04 am
Roche
Vabysmo
diabetic macular edema
wet age-related macular degeneration
FDA Accepts Application for Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)
BioSpace
Tue, 05/9/23 - 12:27 pm
Roche
Genentech
FDA
Vabysmo
macular edema
retinal vein occlusion
Roche’s new eye drug pressures Eylea with strong launch
BioPharma Dive
Wed, 04/26/23 - 05:44 pm
Roche
Vabysmo
Eylea
earnings
Regeneron
Genentech opens up eye patients’ world with Vabysmo
Medical Marketing and Media
Thu, 04/20/23 - 11:40 pm
Genentech
Vabysmo
wet age-related macular degeneration
DTC ads
Trials cue up new use for Roche's eye disease drug Vabysmo
Pharmaphorum
Fri, 02/10/23 - 10:24 am
Roche
Vabysmo
clinical trials
retinal vein occlusion
A year of two halves for US approvals
EP Vantage
Thu, 01/19/23 - 09:38 am
FDA
drug approvals
Mounjaro
Eli Lilly
Vabysmo
Roche
Opdualag
Bristol Myers Squibb
Carvykti
JNJ
Vtama
Roivant
Pluvicto
Novartis
Roche's Vabysmo lands clinical counterpunch in ophthalmology brawl with Eylea
Fierce Pharma
Thu, 10/27/22 - 11:02 am
Roche
Genentech
Vabysmo
bispecific antibodies
Eylea
Look out, Regeneron. As the threat from Roche's Vabysmo grows, one team of analysts slashes its Eylea sales estimate
Fierce Pharma
Mon, 07/25/22 - 10:00 pm
Regeneron
Eylea
Roche
Vabysmo
Regeneron's Eylea could lose 30% of its patients to Roche's Vabysmo over the next year: analyst survey
Fierce Pharma
Mon, 06/13/22 - 09:46 pm
Regeneron
Eylea
Vabysmo
Roche
wet-AMD
The biggest launches of 2022: a reboot
EP Vantage
Mon, 02/14/22 - 10:48 am
drug launches
Eli Lilly
tirzepatide
Alnylam
vutrisiran
Roche
Vabysmo
JNJ
Carvykti
Mirati Therapeutics
adagrasib
Bristol Myers Squibb
mavacamten
deucravacitinib
Roche pharma CEO Anderson talks up Vabysmo’s 'very strong launch' plans as Eylea battle looms
Fierce Pharma
Wed, 02/9/22 - 10:56 pm
Roche
Vabysmo
drug launches
Bill Anderson
Eylea
Roche looks to compete against a blockbuster with its newly approved vision drug
Stat
Sun, 01/30/22 - 11:53 am
Roche
FDA
bispecific antibodies
Regeneron
Vabysmo
wet age-related macular degeneration
diabetic macular edema